Role of FAM83H and its natural antisense transcript FAM83H-AS1 in the occurrence and development of lung adenocarcinoma and ovarian cancer
LIU Mengzhen1 SUN Rongrong2 LIU Yanhua2 ZHANG Youwei2
1.Clinical College, Xuzhou Medical University, Jiangsu Province, Xuzhou 221009, China;
2.Department of Medical Oncology, Xuzhou Central Hospital, Jiangsu Province, Xuzhou 221009, China
Abstract：Objective To investigate the biological roles of FAM83H and its natural antisense transcript FAM83H-AS1 in the occurrence and development of tumor, and the regulatory relationship between them. Methods The expression and prognosis of FAM83H and FAM83H-AS1 in various tumor tissues were analyzed by GEPIA online tool. Logarithmic growth stage A549 and SKOV3 cell lines were selected for transfection and divided into blank control group (control group), no-load control group (siNC group) and experimental group (siFAM83H group, SIFAM83H-AS1 group). The cell proliferation, apoptosis, and migration after FAM83H and Fam83H-AS1 knockdown were compared in each group. Results The expressions of FAM83H and FAM83H-AS1 mRNA were up-regulated in various tumor tissues, including lung adenocarcinoma and ovarian serous cystadenocarcinoma. In lung adenocarcinoma, the survival curves of FAM83H mRNA high expression group and FAM83H low expression group were compared, and the difference was statistically significant (P＜0.05). In A549 and SKOV3 cells, the expressions of FAM83H mRNA and protein in siFAM83H group were lower than those in siNC group (P＜0.05); the expression of FAM83H-AS1 mRNA in siFAM83H-AS1 group was lower than that in siNC group (P＜0.05); cell proliferation in siFAM83H group was lower than that in siNC group after transfection for 24, 48 and 72 h (P＜0.05); the cell proliferation ability of siFAM83H-AS1 group was lower than that of siNC group after transfection for 24, 48 and 72 h (P＜0.05); the apoptosis number of siFAM83H group and siFAM83H-AS1 group was higher than that of siNC group (P＜0.05); the number of cell migration in siFAM83H group and siFAM83H-AS1 group was lower than that in siNC group (P＜0.05). After FAM83H knockdown, there was no significant difference in sIFAM83H-AS1 mRNA between siFAM83H group and siNC group (P＞0.05); after FAM83H-AS1 knockdown, there was no statistical significance in FAM83H mRNA and protein between siFAM83H-AS1 group and siNC group (P＞0.05). Conclusion FAM83H and FAM833H-AS1 play the role of oncogenes in the occurrence and development of lung adenocarcinoma and ovarian cancer, but no mutual regulatory relationship has been found between them, and the specific mechanism remains to be further studied.
刘梦真1 孙蓉蓉2 刘艳华2 张有为2. FAM83H及其天然反义转录本FAM83H-AS1在肺腺癌和卵巢癌发生发展中的作用[J]. 中国医药导报, 2022, 19(36): 4-10,16.
LIU Mengzhen1 SUN Rongrong2 LIU Yanhua2 ZHANG Youwei2. Role of FAM83H and its natural antisense transcript FAM83H-AS1 in the occurrence and development of lung adenocarcinoma and ovarian cancer. 中国医药导报, 2022, 19(36): 4-10,16.
[1] Mattiuzzi C，Lippi G. Current Cancer Epidemiology [J]. J Epidemiol Glob Health，2019，9（4）：217-222.
[2] Kim KM，Park SH，Bae JS，et al. FAM83H is involved in the progression of hepatocellular carcinoma and is regulated by MYC [J]. Sci Rep，2017，7（1）：3274.
[3] Kim KM，Hussein UK，Bae JS，et al. The Expression Patterns of FAM83H and PANX2 Are Associated With Shorter Survival of Clear Cell Renal Cell Carcinoma Patients [J]. Front Oncol，2019，9：14.
[4] Hussein UK，Ha SH，Ahmed AG，et al. FAM83H and SCRIB stabilize beta-catenin and stimulate progression of gastric carcinoma [J]. Aging（Albany NY），2020，12（12）：11812- 11834.
[5] Zhuang H，Zhang C，Hou B. FAM83H overexpression predicts worse prognosis and correlates with less CD8+T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in pancreatic cancer [J]. Clin Transl Oncol，2020，22（12）：2244- 2252.
[6] Chen C，Li HF，Hu YJ，et al. Family with Sequence Similarity 83 Member H Promotes the Viability and Metastasis of Cervical Cancer Cells and Indicates a Poor Prognosis [J]. Yonsei Med J，2019，60（7）：611-618.
[7] Yang Q，Wang J，Zhong P，et al. The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients：a meta-analysis [J]. Cancer Cell Int，2020，20：72.
[8] El-Ashmawy NE，Al-Ashmawy GM，Hamouda SM. Long non- coding RNA FAM83H-AS1 as an emerging marker for diagnosis，prognosis and therapeutic targeting of cancer [J]. Cell Biochem Funct，2021，39（3）：350-356.
[9] Shan H，Yang Y，Zhu X，et al. FAM83H-AS1 is associated with clinical progression and modulates cell proliferation，migration，and invasion in bladder cancer [J]. J Cell Biochem，2019，120（3）：4687-4693.
[10] 缪宇锋，张有为，焦南林.FAM83D在胰腺癌中的表达及临床意义[J].中国医药导报，2021，18（32）：9-12.
[11] Ahn SW，Ahn AR，Ha SH，et al. Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma [J]. Diagn Pathol，2020，15（1）：63.
[12] Ahn AR，Noh SJ，Hussein UK，et al. FAM83H and Nectin1 expression are related with survival and relapse of bladder urothelial carcinoma patients [J]. BMC Urol，2021，21（1）：143.
[13] Kim KM，Hussein UK，Park SH，et al. FAM83H is involved in stabilization of β-catenin and progression of osteosarcomas [J]. J Exp Clin Cancer Res，2019，38（1）：267.
[14] Gan J，Li Y，Meng Q. Systematic Analysis of Expression Profiles and Prognostic Significance for FAM83 Family in Non-small-Cell Lung Cancer [J]. Front Mol Biosci，2020， 7：572406.
[15] Zhao W，Guo J，Li H，et al. FAM83H-AS1/miR-485-5p/ MEF2D axis facilitates proliferation，migration and invasion of hepatocellular carcinoma cells [J]. BMC Cancer，2021， 21（1）：1310.
[16] Ríos-Romero M，Cedro-Tanda A，Pe?觡a-Luna M，et al. FAM83H-AS1 is a potential modulator of cancer driver genes across different tumors and a prognostic marker for ER/PR+BRCA patients [J]. Sci Rep，2020，10（1）：14145.
[17] Han C，Fu Y，Zeng N，et al. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis [J]. Aging（Albany NY），2020，12（4）：3594-3616.
[18] Zhang J，Feng S，Su W，et al. Overexpression of FAM83H- AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer [J]. Sci Rep，2017，7：42819.
[19] Wang S，Han C，Liu T，et al. FAM83H-AS1 is a noncoding oncogenic driver and therapeutic target of lung adenocarcinoma [J]. Clin Transl Med，2021，11（2）：e316.
[20] Gong YB，Zou YF. Clinical significance of lncRNA FAM83H- AS1 in ovarian cancer [J]. Eur Rev Med Pharmacol Sci，2019，23（11）：4656-4662.
[21] Yuan X，Huang Y，Guo M，et al. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer [J]. J Ovarian Res，2021，14（1）：6.
[22] Dou Q，Xu Y，Zhu Y，et al. LncRNA FAM83H-AS1 contributes to the radioresistance，proliferation，and metastasis in ovarian cancer through stabilizing HuR protein [J]. Eur J Pharmacol，2019，852：134-141.
[23] 王高明，刘广军，龚向南，等.长链非编码RNA FAM83A- AS1在肺腺癌组织中的表达水平及与临床病理参数和预后的关系[J].医学研究生学报，2021，34（1）：58-61.
[24] Ayupe AC，Tahira AC，Camargo L，et al. Global analysis of biogenesis，stability and sub-cellular localization of lncRNAs mapping to intragenic regions of the human genome [J]. RNA Biol，2015，12（8）：877-892.
[25] Feng B，Wang G，Liang X，et al. LncRNA FAM83H-AS1 promotes oesophageal squamous cell carcinoma progression via miR-10a-5p/Girdin axis [J]. J Cell Mol Med，2020，24（16）：8962-8976.
京公网安备 11010502046598号